CBF2 Antibody

What is CBF2 and why is it important in research?

CBF2 (also known as CEBPZ) is a CCAAT-binding transcription factor that plays crucial roles in gene regulation. It's alternatively known as CTF2, HSP-CBF, or CCAAT/enhancer-binding protein zeta . The protein is involved in important cellular processes including transcriptional regulation and has been implicated in various biological pathways. Research interest in CBF2 stems from its role in gene expression regulation and potential involvement in disease mechanisms, making CBF2 antibodies valuable tools for investigating these processes .

What applications are CBF2 antibodies validated for?

CBF2 antibodies are primarily validated for Western Blot applications, with some variants also validated for Immunoprecipitation . The Novus Biologicals CBF2 antibody (NBP2-97347JF669) is specifically validated for Western Blot applications in human samples . Another variant (NBP1-71908CL1) is validated for both Immunoprecipitation and Western Blot applications . When selecting a CBF2 antibody, it's critical to choose one validated for your specific application to ensure reliable results.

What conjugated forms of CBF2 antibodies are available?

CBF2 antibodies are available with different fluorescent conjugates to facilitate various detection methods:

These conjugated antibodies eliminate the need for secondary antibodies in many applications, streamlining experimental workflows and potentially reducing background signals .

How should CBF2 antibodies be stored and handled?

Proper storage and handling of CBF2 antibodies is essential for maintaining their efficacy. Based on manufacturer recommendations, CBF2 antibodies should be stored at 4°C in the dark . It's particularly important to protect fluorophore-conjugated antibodies from light exposure to prevent photobleaching. Most formulations contain 0.05% sodium azide as a preservative . Do not freeze these antibodies as this can lead to degradation of both the antibody and the fluorophore conjugate, resulting in diminished performance in experimental applications.

How can optimal dilutions of CBF2 antibodies be determined for Western Blot applications?

Determining the optimal dilution for CBF2 antibodies requires systematic titration experiments. According to product documentation, optimal dilutions should be experimentally determined rather than relying solely on manufacturer recommendations . A recommended approach is to perform a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000) with positive control samples containing known CBF2 expression levels.

For Western Blot optimization specifically:

• Run identical protein samples across multiple lanes

• After transfer, cut the membrane into strips

• Incubate each strip with a different antibody dilution

• Process all strips simultaneously with identical detection conditions

• Compare signal-to-noise ratios to determine optimal dilution

This methodical approach ensures maximum sensitivity while minimizing background, particularly important when working with the fluorophore-conjugated versions of CBF2 antibodies .

What controls should be included when validating a new CBF2 antibody?

When validating a new CBF2 antibody for research applications, several critical controls should be included:

For fluorophore-conjugated CBF2 antibodies, additional autofluorescence controls are recommended to distinguish true signal from background fluorescence, especially in immunofluorescence applications .

How can potential cross-reactivity of CBF2 antibodies be assessed?

Cross-reactivity assessment is crucial for ensuring specificity of CBF2 antibodies. Based on immunological research methodologies:

• Perform comparative Western Blot analysis with recombinant CBF2 and structurally similar proteins

• Utilize knockout or knockdown models where CBF2 expression is eliminated or reduced

• Test antibody reactivity across multiple species to identify potential cross-species reactivity

• Employ epitope mapping to identify the specific binding region and assess potential shared epitopes with other proteins

When evaluating experimental results, molecular weight verification is essential - CBF2 should appear at approximately 42 kDa in Western Blot applications, similar to what has been observed with other nuclear proteins in control experiments . Any additional bands may indicate cross-reactivity or proteolytic degradation that should be systematically investigated.

What are the considerations when using CBF2 antibodies for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) with CBF2 antibodies requires careful optimization to preserve protein-protein interactions while achieving effective precipitation. Key methodological considerations include:

• Buffer composition: Use gentler lysis buffers (e.g., NP-40 or Triton X-100 based) that preserve protein-protein interactions

• Antibody orientation: Consider whether to use the CBF2 antibody as the precipitating antibody or for detection

• Pre-clearing lysates: Implement a pre-clearing step with appropriate control IgG to reduce non-specific binding

• Crosslinking considerations: Determine if chemical crosslinking is necessary to stabilize transient interactions

• Elution conditions: Optimize elution to release protein complexes without contaminating the eluate with antibody chains

The NBP1-71908CL1 variant has been specifically validated for immunoprecipitation applications , making it a preferred choice for Co-IP studies involving CBF2. When interpreting Co-IP results, remember that negative results may reflect technical limitations rather than absence of interaction, necessitating careful optimization of experimental conditions.

How should experiments be designed to compare different CBF2 antibody clones?

When comparing different CBF2 antibody clones or variants, a systematic experimental design is essential:

• Use identical sample preparation methods for all antibodies being compared

• Maintain consistent protein amounts, blocking conditions, and incubation times

• Process all samples in parallel to minimize technical variation

• Include appropriate positive and negative controls for each antibody

• If comparing different conjugates (e.g., Janelia Fluor 669 vs. CoraFluor 1), ensure detection systems are calibrated appropriately

For quantitative comparisons, prepare a standard curve with recombinant CBF2 protein to enable calculation of absolute sensitivity and limits of detection for each antibody. This approach allows for objective comparison between different products like NBP2-97347JF669 and NBP1-71908CL1 .

What factors might affect CBF2 antibody performance in different experimental contexts?

Multiple factors can influence CBF2 antibody performance across different experimental systems:

When troubleshooting inconsistent results across experimental systems, systematically evaluate each of these factors. For fluorophore-conjugated antibodies like the Janelia Fluor 669 or CoraFluor 1 variants, also consider potential fluorescence quenching or enhancement effects from the sample matrix .

How can multiplexed detection involving CBF2 antibodies be optimized?

Multiplexed detection enables simultaneous analysis of CBF2 alongside other proteins of interest. For optimal results:

• Select antibodies from different host species or use directly conjugated antibodies with spectrally distinct fluorophores

• When using CBF2 antibodies conjugated to Janelia Fluor 669 , pair with fluorophores that have minimal spectral overlap

• Implement appropriate compensation controls to correct for spectral overlap in fluorescence-based applications

• Validate antibody combinations to ensure no steric hindrance when targets are in close proximity

• Establish a sequential staining protocol if cross-reactivity between secondary antibodies is observed

For Western Blot applications, consider sequential stripping and reprobing or implement specialized multiplexed Western Blot systems that allow concurrent detection of multiple targets without stripping.

What approaches can resolve discrepancies in CBF2 detection between different antibodies?

When facing discrepant results between different CBF2 antibodies, employ these systematic resolution strategies:

• Epitope mapping: Determine if antibodies recognize different epitopes that might be differentially accessible

• Validation with orthogonal methods: Confirm CBF2 expression using techniques like qPCR or mass spectrometry

• Knockout/knockdown validation: Test antibodies in systems with confirmed CBF2 depletion

• Recombinant expression: Create controlled systems with defined CBF2 expression

• Technical replication: Ensure discrepancies aren't due to technical variability

Remember that polyclonal antibodies like those described in the search results recognize multiple epitopes, which might explain detection differences compared to monoclonal antibodies that recognize single epitopes. Document all protocol variations meticulously when comparing antibody performance to enable accurate interpretation of discrepancies.

How can CBF2 antibodies be integrated into single-cell analysis workflows?

Adapting CBF2 antibodies for single-cell analysis requires specific considerations:

• For flow cytometry: Validate the fluorophore-conjugated CBF2 antibodies (like Janelia Fluor 669 or CoraFluor 1 ) for intracellular staining with appropriate permeabilization protocols

• For mass cytometry (CyTOF): Consider metal-conjugated versions of CBF2 antibodies if available

• For imaging mass cytometry: Optimize tissue preparation to maintain both antigenicity and cellular morphology

• For single-cell Western Blot: Adapt existing Western Blot protocols for microfluidic platforms

Optimization is particularly important when integrating CBF2 detection into multiparameter analyses. Start with established protocols from similar nuclear protein targets and perform systematic parameter optimization, prioritizing both specificity (minimal background) and sensitivity (maximal signal from positive cells).

What are the considerations when using CBF2 antibodies for chromatin immunoprecipitation (ChIP) studies?

While the search results don't specifically validate CBF2 antibodies for ChIP applications, researchers interested in adapting them should consider:

• Fixation optimization: Test multiple formaldehyde concentrations and fixation times

• Sonication parameters: Adjust to achieve appropriate chromatin fragment sizes (200-500 bp)

• Antibody validation: Confirm CBF2 antibody specificity under ChIP conditions using known binding sites

• Controls: Include input, IgG control, and positive control target essential for interpretation

• Sequential ChIP: Consider for co-occupancy studies involving CBF2 and interacting factors

ChIP protocol development should begin with testing antibodies validated for immunoprecipitation, such as the NBP1-71908CL1 variant , as these have demonstrated ability to bind native (non-denatured) protein. Extensive validation would be required before reliable ChIP results could be reported.

How do different detection methods compare when using CBF2 antibodies in research?

Each detection method offers distinct advantages and limitations when working with CBF2 antibodies:

When transitioning between detection methods, expect to perform method-specific optimizations. For example, an antibody performing well in Western Blot may require different conditions for optimal performance in immunofluorescence due to differences in epitope accessibility between denatured and native protein conformations.

What are common troubleshooting approaches for weak or absent CBF2 signal in Western Blot?

When encountering weak or absent CBF2 signal in Western Blot applications, implement this systematic troubleshooting approach:

• Protein extraction optimization:

  • Ensure nuclear proteins are effectively extracted (CBF2 is a nuclear protein)

  • Test different lysis buffers optimized for nuclear protein extraction

  • Add protease inhibitors to prevent degradation

• Western Blot parameter optimization:

  • Increase protein loading (up to 50-100 µg per lane)

  • Reduce antibody dilution (use more concentrated antibody)

  • Extend primary antibody incubation (overnight at 4°C)

  • Optimize blocking conditions to reduce background while preserving signal

• Detection sensitivity:

  • For direct fluorophore-conjugated antibodies (Janelia Fluor 669 or CoraFluor 1 ), ensure appropriate imaging settings

  • Consider signal amplification methods if using HRP-conjugated secondary antibodies

• Antibody validation:

  • Test with positive control samples known to express CBF2

  • Consider epitope accessibility issues that might require alternative antibody clones

Each of these approaches should be tested systematically, changing only one parameter at a time to identify the specific issue affecting detection.

How can researchers evaluate batch-to-batch consistency of CBF2 antibodies?

Evaluating batch-to-batch consistency is critical for longitudinal studies. Implement these quality control measures:

• Reference standard comparison:

  • Maintain aliquots of a reference positive control sample

  • Test each new antibody batch against this standard

  • Document signal intensity and pattern for quantitative comparison

• Quantitative assessment:

  • Use densitometry to quantify Western Blot signals

  • Compare signal-to-noise ratios between batches

  • Establish acceptable variation thresholds (typically ±20%)

• Documentation:

  • Record lot numbers and receipt dates

  • Maintain detailed protocols for consistent testing

  • Document all performance metrics for future reference

• Manufacturer information:

  • Check certificate of analysis for each lot

  • Note any changes in production methods or QC specifications

For fluorophore-conjugated antibodies, additional evaluation of fluorescence intensity and spectral properties is recommended to ensure consistent performance across detection platforms .

How might recent advances in antibody engineering impact CBF2 research?

Recent advances in antibody engineering offer new possibilities for CBF2 research:

• Novel conjugation chemistries: Site-specific conjugation technologies may improve the performance of fluorophore-labeled CBF2 antibodies beyond current Janelia Fluor 669 and CoraFluor 1 conjugates

• Recombinant antibody formats: Single-chain variable fragments (scFvs) or nanobodies against CBF2 could enable applications where conventional antibodies face limitations, such as super-resolution microscopy

• Bispecific antibody formats: Engineered antibodies recognizing both CBF2 and another target could facilitate co-localization studies without requiring secondary antibodies

• Conditional antibodies: Antibodies with activity controlled by environmental factors (pH, light, etc.) could enable precise temporal control of CBF2 detection

These technologies build upon established antibody production methods illustrated in recent literature on monoclonal antibody development , potentially offering enhanced specificity and functionality for CBF2 research applications.

What considerations are important when adapting CBF2 antibodies for tissue-specific studies?

Tissue-specific adaptations for CBF2 antibody applications require careful methodological considerations:

• Tissue preparation optimization:

  • Fixation protocols may need adjustment based on tissue type

  • Antigen retrieval methods should be optimized to expose nuclear epitopes

  • Autofluorescence reduction strategies are essential for tissues with high natural fluorescence

• Validation in relevant tissues:

  • Confirm specificity with appropriate tissue-specific positive and negative controls

  • Consider tissue-specific expression levels when optimizing detection parameters

  • Validate any novel findings with orthogonal methods

• Technical adaptations:

  • Section thickness optimization for adequate antibody penetration

  • Blocking protocol adjustments to address tissue-specific background

  • Incubation time and temperature modifications based on tissue density

Since CBF2 is a nuclear protein, particular attention should be paid to nuclear permeabilization protocols to ensure antibody access to the target while maintaining tissue morphology and avoiding non-specific nuclear staining.

What best practices should researchers follow when reporting CBF2 antibody usage in publications?

To ensure reproducibility and proper interpretation of results, researchers should adhere to these reporting guidelines when publishing studies utilizing CBF2 antibodies:

• Detailed antibody information:

  • Complete catalog number including conjugate designation (e.g., NBP2-97347JF669 or NBP1-71908CL1 )

  • Manufacturer/supplier name

  • Lot number when available

  • Clonality (polyclonal vs monoclonal) and host species

• Method-specific details:

  • Antibody dilution used

  • Incubation conditions (time, temperature, buffer composition)

  • Detection systems employed

  • Image acquisition parameters for fluorescence-based applications

• Validation details:

  • Controls included (positive, negative, isotype)

  • Any validation experiments performed

  • Known limitations or cross-reactivity

• Complete experimental conditions:

  • Sample preparation methods

  • Buffer compositions

  • Blocking reagents and conditions